Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there? Here's what to know.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

If colleges close themselves off to economic changes from scientific progress and digital transformation, they’re likely to ...

Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.

Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay programs at $499 monthly ...